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Abstract. Words: 278 
Background/ Aims 
During the 2014-2016 West African Ebola epidemic, clinical trials were fast-tracked in order to 
identify prophylactic vaccines and experimental treatments that might be useful in preventing or 
treating Ebola. These trials included the ongoing EBOVAC-Salone study, which was established and 
implemented in Sierra Leone to assess the safety and immunogenicity of the Ad26.ZEBOV/MVA-BN-
Filo prime-boost Ebola vaccine regimen.  
Methods 
This paper describes the experiences of the EBOVAC-Salone research team in setting up and 
implementing the trial, and provides recommendations for research teams aiming to conduct clinical 
trials in future outbreak situations.   
Results 
Establishing a clinical trial during an outbreak brought some unique challenges, including those 
related to trial design and the regulatory environment, operational issues, and community 
engagement. The situation was further complicated by the weak infrastructure and limited 
experience of clinical trials in Sierra Leone. However, operating in an outbreak context also brought 
some benefits to the research team, including strong stakeholder support. The EBOVAC-Salone study 
recruited participants both during and after the outbreak, leading to additional challenges to trial 
implementation during the post-outbreak transition. 
Conclusions 
Many lessons have been learned about setting up and implementing a clinical trial during a 
devastating Ebola epidemic, and some of the experiences of the EBOVAC-Salone team were 
mirrored by those of other researchers operating in the region. Common to several of these 
research groups is a recommendation that research should be more closely incorporated into 
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outbreak response planning, which could expedite the establishment of timely and appropriate 
research projects. We recommend that the lessons learned by researchers during the West Africa 
Ebola epidemic are built into programmes and strategies to improve the responses to future 
epidemics, wherever they occur. 
Key words: Ebola, vaccine, trial, Sierra Leone, lessons, epidemic, recommendations 
 
Trial registry name: Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola 
Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stage 1 and 2 
(EBOVAC-Salone). 
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Background 
The scale of the 2014-2016 West African Ebola outbreak was unprecedented.  Over 28,000 people 
were infected across Guinea, Liberia and Sierra Leone, 11,300 of whom died. 1 As part of the global 
response, clinical trials of experimental treatments and prophylactic vaccines were fast-tracked for 
testing. 
In December 2014, the Innovative Medicines Initiative awarded funding from the Ebola+ programme 
to the EBOVAC1 consortium of research institutions in partnership with the Janssen Pharmaceutical 
Companies of Johnson & Johnson (Janssen) to support the development and evaluation of a prime-
boost prophylactic Ebola vaccine regimen.2, 3 The EBOVAC-Salone study in Sierra Leone, which is still 
ongoing, is part of the EBOVAC1 project.  
The EBOVAC-Salone study is assessing the safety and immunogenicity of the Ad26.ZEBOV/MVA-BN-
Filo prime-boost regimen in a population affected by Ebola, and is being carried out in Kambia 
District in northern Sierra Leone. It is coordinated by the London School of Hygiene &Tropical 
Medicine, in collaboration with the College of Medicine and Allied Health Sciences in Sierra Leone, 
and is sponsored by Janssen. The Innovative Medicines Initiative is also funding the related EBODAC 
(Ebola Vaccine Deployment, Acceptance and Compliance) consortium which supports community 
engagement for the EBOVAC-Salone trial, amongst other activities.4  
Collaborations for the EBOVAC-Salone study were established quickly between November 2014 and 
March 2015 in an emergency context in which the Ebola epidemic was still claiming lives across 
Sierra Leone. Vaccination of adult trial participants began on 9 October 2015. The study is ongoing 
and has recruited and vaccinated participants both before and after the end of the Ebola epidemic, 
declared by the World Health Organisation on 7 November 2015.  
This paper offers observations on some of the challenges encountered and lessons learned while 
setting up and recruiting participants into a clinical trial during and after an epidemic, and makes 
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recommendations on how these could be addressed in the future should a similar public health 
emergency arise. Several research groups have published their own experiences of conducting 
clinical trials during the Ebola outbreak, and the literature paints a picture of the context within 
which the EBOVAC-Salone trial was established. A number of researchers have described the 
difficulty of designing a robust yet ethical trial during an outbreak,5, 6 and then having to amend or 
abandon their original study objectives as the epidemic waned.5, 7 Others highlighted the limitations 
imposed by the infrastructure of the country in which they were operating.5 The challenges were not 
just for researchers: The burden on local ethics committees, dealing with huge increases in 
workload, was also noted.7-9 
 
While many of the challenges and lessons described in this paper have been shared by other 
researchers, this paper makes a novel contribution to the literature as one of the few trials to enrol 
participants both during and after the epidemic. This gives the authors an additional perspective into 
issues such as community engagement, participant recruitment and trial design, all of which were 
affected by the end of the outbreak. 
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Methods and Results 
Trial design  
The design of the EBOVAC-Salone study was revised on several occasions in response to the 
evolution of the Ebola epidemic. During the epidemic’s peak in 2014, an 80,000-person, individually 
randomised, controlled trial was considered briefly that aimed to determine the efficacy of the 
Adv26.ZEBOV/MVA-BN-Filo regimen compared to a control vaccine. However, administration of a 
placebo during a viral outbreak with such a high case-fatality rate had never been done before, and 
the ethics of this were hotly debated.10 
Alternative trial designs were considered, including a cluster-randomised trial and a stepped-wedge 
design.11 In January 2015, taking into account ethical concerns, the epidemic circumstances, field 
conditions and statistical considerations, the trial was redesigned as a large cluster-randomised trial 
of approximately 800,000 participants, to be randomised to receiving either immediate or delayed 
vaccination. Regulatory authorities in Sierra Leone requested a staged approach to recruitment to 
first determine the safety of the vaccine, with initial enrolment of 40 adults who were to be offered 
immediate vaccination (Stage 1), followed by enrolment of 400 adults (Stage 2) before commencing 
the main cluster-randomised trial.11 
Site visits and mathematical modelling were used to help determine both the sample size and 
geographical location of the study. By the first quarter of 2015, the epidemic was slowing and it was 
important to determine whether there would be a sufficient number of cases to determine vaccine 
efficacy. Kambia District in northern Sierra Leone was chosen as the site for the study because no 
other prophylactic vaccine trial was underway in that part of the country, and because modelling 
data predicted a 50% probability of the epidemic being over in Kambia District by October 2015, 
compared to a 75% likelihood in Port Loko and Western Area, the other districts under 
consideration, by August 2015. 
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However, the epidemic declined at a faster rate than expected during the first quarter of 2015 
throughout Sierra Leone. By May 2015, it was clear that the study would be unable to determine 
vaccine efficacy. The cluster-randomised trial protocol was therefore abandoned before it was 
approved by the regulatory authorities and the primary objective for the study was changed to 
determination of the safety and immunogenicity of the regimen,11 with an estimated sample size of 
approximately 3,500 participants. Stage 1 was kept as open label vaccination of 40 healthy adult 
participants. In December 2015, following the end of the outbreak, the use of placebo was 
reintroduced to the study design. Stage 2 was formally amended to a double-blind randomised 
controlled trial assessing the safety and immunogenicity of the vaccine regimen, with follow-up for 
12 months and a sample size of approximately 730 participants. Enrolment of 400 adults 
(randomised in a 3:1 ratio of Ad26.ZEBOV/MVA-BN-Filo to MENVEO®) has been followed by an age 
de-escalation component for paediatric participants.  
The changes to the trial design affected many aspects of the study beyond what is typically 
encountered in the setup phase of a trial. As the trial design evolved, budgets underwent multiple 
revisions, and project plans changed significantly while the team waited for approvals, with 
associated amendments to orders and procurement of equipment and consumables. The 
expectations of stakeholders and community members had to be managed as the study enrolment 
target was significantly reduced which shrank the study’s geographical footprint from an initial 
district-wide catchment area, to just the inhabitants of two of the district’s main towns. 
Partnerships  
The time pressures of operating during an outbreak influenced how partnerships in Sierra Leone 
were established, and the study was implemented by organisations which had not previously 
worked together. Partners in-country were needed quickly to provide local leadership and expertise, 
and to implement field activities for the trial. After discussions with Sierra Leone’s Ministry of Health 
and other stakeholders, a research partnership was established with the University of Sierra Leone’s 
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College of Medicine and Allied Health Sciences. However, College of Medicine staff had limited 
experience of clinical trials and therefore significant technical support was required from the London 
School of Hygiene & Tropical Medicine and the trial sponsor. 
Two non-governmental organisations also worked on the trial. Goal joined as the trial’s logistics 
partner, while World Vision were engaged to provide community engagement and IT support. 
Clinical research is outside of the usual remit of these organizations, and therefore it was essential 
that all partners understood the others’ requirements and limitations from the beginning of the 
project. 
Regulatory and ethics reviews 
EBOVAC-Salone study approvals were required from the London School of Hygiene & Tropical 
Medicine Ethics Committee, the Sierra Leone Ethical and Scientific Review Committee and the 
Pharmacy Board of Sierra Leone the national regulatory authority.  During the Ebola epidemic the 
African Vaccine Regulatory Forum, with support from the World Health Organization, established a 
platform for conducting joint reviews of clinical trial applications with input from international 
regulatory agencies. This aimed to achieve rapid comprehensive reviews of clinical trials in the 
context of potentially limited regulatory and ethics review capacity in the sub-Saharan African 
countries participating in Ebola vaccine trials.12 The EBOVAC-Salone study team engaged with the 
African Vaccine Regulatory Forum review process at a meeting in April 2015 that was also attended 
by the Pharmacy Board of Sierra Leone and the Sierra Leonean ethics committee.  
During the epidemic, the ethics committees and the Pharmacy Board implemented an expedited 
review process for Ebola-related studies. Both Sierra Leonean authorities experienced a dramatic 
rise in workload in 2014-2015 as they were receiving frequent submissions for Ebola-related 
research. Despite this, the authorities continued to give thorough reviews and completed most 
reviews within one month following submission. The sponsor and study team engaged the 
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authorities from the start of the project, to prepare them for the possibility of study design changes 
in response to the evolving epidemic.  
Ethical considerations 
Shortly after the Ebola epidemic was declared a Public Health Emergency of International Concern 
the World Health Organization established a panel of experts to discuss ethical questions relating to 
the use of unproven interventions, with discussions held around appropriate trial designs during an 
outbreak.13 Both the World Health Organization’s ethics panel and a group of expert anthropologists 
issued guidance to research groups planning to conduct clinical trials during the epidemic.14  
An overarching ethical concern was that clinical research should not impact on the health system or 
the emergency response. The World Health Organisation coordinated prioritisation of the most 
promising research, so as not to overburden the health systems in the affected countries.15 In Sierra 
Leone, planning for the EBOVAC-Salone study was undertaken in partnership with the College of 
Medicine and Allied Health Sciences, and a criterion was set that health care workers involved in the 
emergency response would not be recruited to the study team. Senior staff were therefore recruited 
from overseas to provide technical support, while also building the experience of more junior 
national staff who had not previously been involved in clinical research.  
The question of whether trials should be placebo-controlled was particularly contentious,16-19 
although not a new debate.19 During initial discussions held in Sierra Leone in early 2015 by the 
EBOVAC-Salone team, the country’s authorities did not favour a randomised placebo-controlled trial 
and this ethical concern informed the study design as discussed above. In common with some other 
Ebola vaccine trials taking place in the region, the research team therefore developed an innovative 
trial design to study efficacy without the use of a placebo. This trial design was never implemented, 
because the epidemic’s decline made it impossible to establish vaccine efficacy before this study 
could be initiated. 
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Further ethical issues became apparent once the study began. EBOVAC-Salone social science 
research indicated that one of the motivating factors for participation in the trial was an expectation 
that the vaccine would be effective. The research team addressed this by placing additional 
emphasis on the investigational nature of the vaccine during community outreach activities and the 
informed consent process. The latter included a test which participants had to pass before being 
enrolled to demonstrate their understanding of the trial. 
Initial participant recruitment took place prior to the end of the epidemic, and demand to 
participate in the study at that time was greater than the number of participants needed. To ensure 
fair subject selection, a lottery system was devised whereby households were selected and 
prioritised in an open ballot.20 An age de-escalation approach was adopted with safety data being 
reviewed by an independent data monitoring committee prior to the enrolment of each cohort of 
children. Pregnant women were excluded from the because of concerns over the safety of viral 
vaccines given during pregnancy. This exclusion criterion was common to all Ebola vaccine trials in 
the region, although some authors have argued that, in future, pregnant women should not be 
denied the potential benefits of participating in clinical research in an outbreak of such high 
mortality.21 
Communications and engagement 
The normal processes of engaging with communities prior to a trial of a new investigational medical 
product were given an additional layer of complexity by the Ebola outbreak. The challenges of 
community engagement and building trust and awareness in a setting with no experience of clinical 
trials, such as Kambia, were exacerbated by the urgency to commence the research.  
Formative, qualitative research into community dynamics, and perceptions around Ebola and the 
clinical trial was especially important during a period that was characterised by a lack of trust in both 
national and international organisations.22 This research, and ongoing tracking of rumours and 
concerns, helped target engagement approaches and community messaging. For example, a rumour 
that the vaccine trial was bringing Ebola back to the community, nicknamed ‘Ebola Phase Two’, was 
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identified by the social scientists. The community liaison team responded by visiting the market 
where the rumour had originated and initiating meetings to address the concerns with the support 
of pre-briefed local stakeholders. 
Establishing the study while the emergency response infrastructure was in place was challenging for 
the study’s community engagement in some ways, but facilitated it in others. The Ebola response 
centres brought stakeholders together, providing an efficient mechanism through which these 
individuals could be briefed. Because many stakeholders were already engaged in the fight against 
Ebola, they were often particularly receptive to research teams.  
However, in an environment where people were desperate for solutions, the study’s community 
engagement had to clearly differentiate the research project from the Ebola response to avoid 
possible misinterpretations that the trial was delivering a licensed vaccine as part of the 
humanitarian response.  
Participant recruitment 
During the outbreak, community interest in participating in the first stage of the study was high. 
EBOVAC’s social science research indicated a range of motivating factors behind participation in the 
early stages of the trial, including the notion of ‘sacrifice’ or duty as a citizen; and hope or belief in 
the power of the vaccine to prevent Ebola. 
Contrary to the experience of some groups conducting research during the outbreak, generous 
financial compensation was not necessary to stimulate participation in the trial in Kambia.8 Study 
partners sought advice from the national ethics committee before agreeing to rates that would fairly 
recompense a participant’s time and transport without providing undue inducement, based on 
estimated lost earnings and transport costs to and from the clinic. 
Human resources 
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The limited pool of clinicians in Sierra Leone was severely affected by the outbreak as Ebola-related 
mortality amongst health workers was particularly high.23 Prior to the epidemic, Sierra Leone ranked 
5th from bottom among 193 countries in terms of numbers of physicians per head of population.24 
As discussed above, so as not to further weaken the wider health system, the research team 
committed not to recruit any healthcare workers employed in the government health system or 
involved in the Ebola response without the approval of the appropriate authorities.  
 
Because limited clinical research had been conducted in Sierra Leone prior to the Ebola epidemic, 
there were very few individuals in the country with appropriate research experience, and those that 
had this were generally involved in other Ebola-related studies. Technical and scientific support was 
therefore provided to the in-country team, facilitated by the London School of Hygiene & Tropical 
Medicine’s response to the epidemic that allowed staff to temporarily leave their current post to 
work on the Ebola response. 
 
It proved challenging to attract suitably qualified and experienced applicants to work in longer term 
positions on the trial. This may have been due to the perceived risk of working in an Ebola-affected 
country; because the trial site was in a relatively undeveloped district; and because people with the 
relevant skills were not available to apply for posts at short notice. In addition, the London School of 
Hygiene & Tropical Medicine is not an emergency response organisation and therefore did not 
provide hardship or risk allowances to staff employed on the study. 
 
Operational issues 
Many operational challenges arose because the epidemic occurred in a region with a low level of 
development; Sierra Leone remains among the world’s poorest countries and suffers from poor 
infrastructure.25 Outside an outbreak situation, a rural district like Kambia would not be a natural 
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choice for an urgent trial due to the extensive requirements and costs of delivering a Good Clinical 
Practice-compliant study in this setting.  
Kambia is not on the national power grid and therefore a 24-hour generator-based power supply 
was installed for vaccine storage, offices and laboratories, and a fuel supply-chain and fuel store 
were established. Whilst it was possible to rent, renovate and equip existing buildings for the 
research clinics and offices, it was necessary to construct a vaccine storage facility and establish a 
research laboratory. Logistics became hugely time-consuming, necessitating dedicated operations 
staff to oversee construction, electrical installations and laboratory set-up. In common with many 
emergency situations, the cost of accommodation, rental and construction of buildings, and goods 
such as furniture rose substantially with the arrival of Ebola response partners. 
Emergency public health restrictions implemented to curtail the spread of Ebola affected the 
establishment of the study. For example, nightly curfews limited working hours, including on the 
study-related construction and renovations, and restricted the movement of people and vehicles 
throughout the country.  
However, engagement with the Ebola response authorities allowed the team to gain special 
dispensation to assist with setting up the research project. These included securing permits to allow 
team members to travel during curfew periods in Kambia; and a blanket exemption on import tax for 
equipment and consumables. 
 
Post-outbreak transition 
The EBOVAC-Salone trial is now in the age de-escalation stage of the trial, and has experienced the 
transition from working in an outbreak setting to a post-outbreak setting, and the return to ‘business 
as usual’.  
The response infrastructure in Sierra Leone was quickly dismantled once the outbreak ended and the 
stakeholder landscape changed almost overnight as roles and responsibilities at national and district 
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level reverted to their pre-Ebola position. The study team had to reassess the potential influence of 
various individuals or institutions on the trial and adjust relationships accordingly. 
The dispensations related to the emergency situation were suspended rapidly once the outbreak 
was declared over. This included the waiver on importation taxes, which was not clearly 
communicated to the research team, thereby complicating the clearing of a subsequent shipment. 
After the outbreak had ended, interest in study participation decreased, in part due to a shift in the 
risk/benefit perception of members of the community, many of whom felt that Ebola had been 
eradicated permanently. The household lottery method for recruiting participants was therefore 
expanded and a broader ‘first come, first served’ approach was adopted. 
Post-outbreak, many of the logistical challenges remain such as the lack of a mains power supply, 
and staff recruitment and retention to a relatively remote area of the country. Despite these 
challenges, the study completed enrolment of adult participants in October 2016 and is recruiting 
participants into the age de-escalation component of the trial. Over 100 Sierra Leonean study 
personnel, including some Kambia Government Hospital staff, have been trained in essential 
research skills and clinical management. This will hopefully provide a legacy and a platform on which 
to build further research in the district. 
 
Recommendations and Conclusions 
Following the experiences of establishing the EBOVAC-Salone trial and the lessons learned between 
2014 and 2017, we have a number of recommendations for teams aiming to conduct research 
during epidemics. 
Trial design. Research teams, funders, regulatory authorities and ethics committees should be 
flexible and prepared for additional workloads when initiating and implementing clinical trials in 
outbreak settings, as trial designs may need to be adapted and submitted for review several times 
over a short period. Modelling can be utilised to predict trends and help identify research sites as 
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the epidemic unfolds. For trials of investigational medical products, study design changes may 
continue after an epidemic ends as the advice of international regulatory authorities may also 
change if the results of the trial are part of the submission for licensure. There is now a substantial 
body of information regarding the acceptability of outbreak-specific trial designs from the Ebola 
epidemic that could be used to inform template trial designs in advance of future outbreaks.   
Partnerships. Identifying partnerships with established, on-the-ground organisations may require 
urgent networking and meetings to build trust and agree goals if partners have not worked together 
before. Linkages with organisations that are not necessarily ‘classical’ research partners can be 
extremely valuable for implementing research in an emergency situation.  
Regulatory and ethics reviews. Ethical and regulatory authorities in countries with limited experience 
of clinical trials or other studies conducted during an epidemic may need to be supported by 
regional and international bodies to develop guidelines for study submissions during epidemics. 
Additional funding may be required to increase capacity for urgent reviews. The African Vaccine 
Regulatory Forum and similar bodies can usefully support ethics committees and regulators to 
facilitate the review and approval of clinical trials conducted during an epidemic if utilised at the 
right time, and sponsors and researchers should engage early with such a forum.  
Ethical considerations. Experiences around ethical issues pertaining to the design and 
implementation of clinical trials during the Ebola epidemic should be considered for future 
outbreaks. As soon as an outbreak is declared, the potential need for appropriate research should be 
considered as an integral part of the response planning to ensure that possible ethical concerns 
come to the fore and are debated at the first possible opportunity. Research must not have a 
detrimental impact on either the outbreak response or health systems.  
Communications and engagement. Social scientists should be considered an integral part of any 
large clinical trial team, particularly for trials in an outbreak situation where it is vital to understand 
community dynamics and concerns that may change frequently.  
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During an outbreak, additional efforts may be needed to explain and reinforce the distinction 
between an investigational medical product and a licensed treatment or vaccine, especially when 
fear of infection may be more likely to influence participant decision-making.  
Participant recruitment. Interest in participation may fluctuate based on community perceptions of 
risk associated with the outbreak and the benefits of participation, and recruitment strategies may 
therefore need to be adapted as epidemics evolve or wane. 
Human resources. Researchers should engage local health authorities to establish guidelines for 
recruiting staff to prevent weakening outbreak responses or health systems. Recruitment of certain 
cadres of staff from countries or areas not affected by the outbreak may need to be considered, at 
least temporarily.  
Operational issues. During an outbreak, researchers may need to choose study sites that are not 
ideal in order to conduct the study in a suitable target population while avoiding other research 
projects. Researchers should respect emergency restrictions, but may be able to explore 
dispensations with the public health authorities if they do not pose a risk to outbreak control 
activities. Researchers should establish what happens to these dispensations should the outbreak 
end.  
Post-outbreak transition. Researchers should ensure that they identify and engage both routine and 
response structures and government regulations to help ensure continuity of support and trial 
activities once an outbreak is over. 
Conclusion 
Many challenges have been identified while setting up and implementing clinical trials during the 
West African Ebola epidemic. We found that, despite implementing a study with new research 
partners in a district with poor infrastructure and health services, where clinical research is in its 
infancy, interest in participation was high. The EBOVAC-Salone study has enrolled a total of 443 
17 
 
adults, 192 adolescents, and 132 children between October 2015 and December 2017, and the study 
continues to enrol younger cohorts of participants. 
However, in common with other research groups, we recommend that research should be more 
closely involved in outbreak response planning, which could expedite the establishment of research 
projects and maximise their chances of success. 
While many of the lessons learned from the EBOVAC-Salone experience will be specific to the 
context of the Ebola outbreak in Sierra Leone, it is hoped that the principles behind them are 
transferable to research teams in other outbreak situations. These recommendations could be 
added to programmes and strategies to improve the responses to future epidemics.  
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